Meng, US
Andrew E. Meng, Towson, MD US
Patent application number | Description | Published |
---|---|---|
20080216280 | UTILITY VACUUM - A vacuum that includes a container, a hose in fluid communication with the container, a fan assembly coupled to the container, an attachment and an accessory apron. The fan assembly includes a fan housing and a fan that is configured to draw a debris-laden air flow through the hose and into the container. The attachment is capable of being releasably coupled to at least one of the hose and the fan housing. The accessory apron has a strap and a holder that is sized to receive and removably store the attachment. The strap is configured to be releasably secured to at least one of the canister and the fan assembly. | 09-11-2008 |
20100058553 | Utility Vacuum - A utility vacuum that may be configured to employ a disposable bag or removable and reusable container for the collection of dirt and debris that are drawn into the utility vacuum. The utility vacuum may employ one or more movable legs that are movable between an extended position, which provides relatively stable operation of the utility vacuum, and a retracted position, which reduces the footprint of the utility vacuum so that it is easier to store. | 03-11-2010 |
Charles O. Meng, Alpharetta, GA US
Patent application number | Description | Published |
---|---|---|
20080214660 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 - This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases. | 09-04-2008 |
Charles Q. Meng, Duluth, GA US
Patent application number | Description | Published |
---|---|---|
20080280974 | Spiro compounds for treatment of inflammatory disorders - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: | 11-13-2008 |
20090270454 | Sulfonamide containing compounds for treatment of inflammatory disorders - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: | 10-29-2009 |
Charles Q. Meng, Johns Creek, GA US
Patent application number | Description | Published |
---|---|---|
20100144859 | DIMERIC AVERMECTIN AND MILBEMYCIN DERIVATIVES - This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections and infestations in animals or for combating pests in plants or plant propagation material. | 06-10-2010 |
20110245157 | DIMERIC 1-ARYLPYRAZOLE DERIVATIVES - This invention provides for dimeric1-arylpyrazole compounds, of formulas (I), (II), and (III): | 10-06-2011 |
20120283094 | PESTICIDAL BIS-ORGANOSULFUR COMPOUNDS - The present invention provides bis-organosulfur compounds of formulae (I) and (II) and compositions comprising the compounds that are effective against animal pests, including parasites. The compounds and compositions may be used for combating parasites in or on birds and mammals and for combating pests that damage crops, plants and plant propagation material. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals. | 11-08-2012 |
20130281392 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF - The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof. | 10-24-2013 |
20130281710 | PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS - Provided are improved processes for the preparation of 1-aryl pyrazole compounds of formula (I) and (IB): | 10-24-2013 |
20140142114 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF - The present invention relates to novel anthelmintic compounds of formula (I) below: | 05-22-2014 |
20140303220 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND A SUBSTITUTED IMIDAZOLE, METHODS AND USES THEREOF - This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof. | 10-09-2014 |
Christopher Meng, Gainesville, FL US
Patent application number | Description | Published |
---|---|---|
20110200172 | METHOD AND APPARATUS FOR COMPUTED IMAGING BACKSCATTER RADIOGRAPHY - Systems and methods of x-ray backscatter radiography are provided. A single-sided, non-destructive imaging technique utilizing x-ray radiation to image subsurface features is disclosed, capable of scanning a region using a fan beam aperture and gathering data using rotational motion. | 08-18-2011 |
Chung Meng, Rochester, MN US
Patent application number | Description | Published |
---|---|---|
20090132550 | IMPLEMENTING SERVICE REQUESTS FROM A COMMON DATABASE IN A MULTIPLE DHCP SERVER ENVIRONMENT - A method and apparatus are provided for implementing service requests from a common database in a multiple dynamic host configuration protocol (DHCP) server environment. A DHCP authorization cache is provided to implement synchronized access for the multiple DHCP servers to the common database. The DHCP authorization cache includes a plurality of elements, each element for storing a plurality of entries including a client identifier, an ISCSI DHCP router pointer, an ISCSI DHCP router pointer alternate, and a timestamp and the DHCP authorization cache includes an entry pointer initially set to zero. | 05-21-2009 |
Desheng Meng, Houghton, MI US
Patent application number | Description | Published |
---|---|---|
20120148931 | SELF-PUMPING MEMBRANELESS FUEL CELL - The present invention is directed to a device, and method of operation, for a fuel cell which uses bubble-based pumping to self-pump the fuel to the anode, and a single, common channel separating the anode from the cathode through which a mixed fuel and electrolyte flow. The fuel cell includes a single channel having two of its sides formed by the anode and the cathode, each having a suitable catalyst. A bubble generating region is formed in the anode and cathode reaction area of the channel. A one-way valve is located upstream of the bubble generating region. A vent for venting bubbles is disposed over a portion of the channel downstream of the bubble generating region. The fuel cell may be advantageously used to build miniature fuel cells for miniature electronic devices, or scaled to build larger fuel cells for larger electronic devices. | 06-14-2012 |
Dongfang Meng, Westfield, NJ US
Patent application number | Description | Published |
---|---|---|
20090163559 | Estrogen receptor modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate. | 06-25-2009 |
20100113439 | Antifungal agents - Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions. | 05-06-2010 |
20100168188 | Estrogen Receptor Modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate. | 07-01-2010 |
20100240721 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF - The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. | 09-23-2010 |
20110224228 | ANTIFUNGAL AGENTS - Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions. | 09-15-2011 |
20110263663 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF - The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. | 10-27-2011 |
Fan Meng, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20080199866 | SNP DETECTION AND OTHER METHODS FOR CHARACTERIZING AND TREATING BIPOLAR DISORDER AND OTHER AILMENTS - The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia. | 08-21-2008 |
20090019557 | FGF2-RELATED METHODS FOR DIAGNOSING AND TREATING DEPRESSION - The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness. | 01-15-2009 |
20110104674 | SNP DETECTION AND OTHER METHODS FOR CHARACTERIZING AND TREATING BIPOLAR DISORDER AND OTHER AILMENTS - The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia. | 05-05-2011 |
Fanli Meng, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20100224109 | BOTTLE FURNACE - A method and apparatus to batch de-coat the organics in metal scrap, and/or gasify the organics from certain types of waste material (including biomass, municipal solid waste, industrial waste, and sludge). The apparatus is suited for use on a batch tilting single entry rotary furnace of the type used to melt the metal scrap in the aluminum industry. The apparatus uses a burner in the tilting rotary furnace but does not necessarily melt the metal scrap. It preferably operates below the melting temperature of the metal scrap (<1400 F) and below the stoichiometric level (more specifically <12% oxygen) to partially combust the organic in the tilting rotary furnace. The gasified organics depart the furnace in a complete closed circuit where no air is allowed to entrain into the flue gases. These organic filled gases (synthetic gases) are fully incinerated in a separate thermal oxidizer where a stoichiometric burner uses either natural gas or liquid fuel to ignite the synthetic gas. The system can identify when the organics are fully gasified, and the metal scrap is fully clean. | 09-09-2010 |
Fanli Meng, Cranford, NJ US
Patent application number | Description | Published |
---|---|---|
20120118106 | GAS BARRIER - An apparatus for processing material such as organically coated waste and organic materials including biomass, industrial waste, municipal solid waste and sludge, is provided. The apparatus comprises a rotatable and tillable furnace ( | 05-17-2012 |
Guangqing Meng, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20100072555 | WAFER BONDING METHOD AND WAFER STACK FORMED THEREBY - A wafer bonding process that compensates for curvatures in wafer surfaces, and a wafer stack produced by the bonding process. The process entails forming a groove in a surface of a first wafer, depositing a bonding stack on a surface of a second wafer, aligning and mating the first and second wafers so that the bonding stack on the second wafer contacts a bonding site on the first wafer, and then heating the first and second wafers to reflow the bonding stack. The groove either surrounds the bonding site or lies entirely within the bonding site, and the heating step forms a molten bonding material, causes at least a portion of the molten bonding material to flow into the groove, and forms a bonding structure that bonds the second wafer to the first wafer. Bonding stacks having different lateral surface areas can be deposited to form bonding structures of different heights to compensate for variations in the wafer gap. | 03-25-2010 |
Haiwen Meng, Phoenix, AZ US
Patent application number | Description | Published |
---|---|---|
20100266424 | INFLATION ASPIRATOR WITH COLLAPSIBLE BARREL - An aspirator for inflating an aircraft evacuation slide, emergency raft or other inflatable device includes a flexible, collapsible aspirator barrel that is inflated during operation to form a substantially rigid tube. According to one embodiment, the inflatable support member receives a flow of high pressure air directly from the aspirator injector nozzle assembly. According to another embodiment, the collapsible aspirator barrel receives a flow of high pressure gas directly from the high pressure inflation source. Because the aspirator barrel of the present invention is collapsible, the present invention occupies significantly less space when stored than an equivalent aspirator with a rigid aspirator barrel. | 10-21-2010 |
Haiying Meng, New Haven, CT US
Patent application number | Description | Published |
---|---|---|
20080318217 | Identification of Gene Associated with Reading Disability and Uses Therefor - The present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD. | 12-25-2008 |
He Meng, Newtonville, MA US
Patent application number | Description | Published |
---|---|---|
20090326196 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same - One aspect of the invention relates to a polypeptide comprising at least one fluorinated amino acid. Another aspect of the invention relates to a method for modifying a first polypeptide, comprising replacing at least one amino acid in said first polypeptide with a fluorinated amino acid, thereby producing a second polypeptide with increased stability relative to said first polypeptide. | 12-31-2009 |
Hongxing Meng, Cumming, GA US
Patent application number | Description | Published |
---|---|---|
20090208206 | SYSTEMS AND METHODS FOR PRIVATE NETWORK-TO-NETWORK INTERFACE OUT-OF-BAND SIGNALING AND PATH BLOCKING - The present invention provides systems and methods to mix In-Band (IB) and Out-of-Band (OOB) signaling mechanisms under the Private Network-to-Network (PNNI) protocol for optical control plane connectivity. The present invention provides mechanisms for establishing and controlling OOB control plane communications. By default, the mechanisms treat all links as IB to discover nodes and links using IB mechanisms. For any blocked links, the link can be configured as OOB if there is a data communication network (DCN) connection to the remote node | 08-20-2009 |
20130129345 | OPTICAL TRANSPORT NETWORK SYNCHRONIZATION AND TIMESTAMPING SYSTEMS AND METHODS - The present disclosure provides to Optical Transport Network (OTN_ synchronization systems and methods that maintain proper sequential ordering of events at nodes which may be utilized in performing root cause analysis or diagnosing network performance. In an exemplary embodiment, the systems and methods utilize functionality incorporated into OTN providing a cost effective and standards-based approach to nodal synchronization. Once synchronized, network events are logged with an appropriate timestamp enabling a determination of a sequential order of network events can be determined. Further, the node timestamps may be synchronized, with microsecond or even sub-microsecond of precession which is critical in diagnosing network failures or slow traffic recovery. | 05-23-2013 |
20140186019 | METHODS AND SYSTEMS OF PRESERVING CLIENT OVERHEAD BYTES IN OPTICAL TRANSPORT NETWORK TUNNELING APPLICATIONS - A method, a network, and a node each implement the transmission of Automatic Protection Switching (APS) switching coordination bytes across an OTN network. A working signal and a protection signal are received, one of which is designated as an active signal. The active signal is encapsulated in an Optical channel Data Unit (ODU) signal. APS switching coordination bytes from the working and protection signals are placed in an overhead segment of the ODU signal. The ODU signal is transmitted into and received from an Optical Transport Network (OTN) network. The working and protection signals are recreated based on the active signal encapsulated in the ODU signal and the APS switching coordination bytes in the overhead segment. The recreated working and protection signals are transmitted. In this manner, a single ODU signal may be used to transmit both the working and protection signals. | 07-03-2014 |
James C. Meng, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20090211274 | Process and apparatus for pretreatment of fresh food products - A method and apparatus for pretreating a fresh food product to relieve the internal (turgor) pressure and adjust the product temperature has an enclosure with an internal space, an air inlet and an air outlet. An exhaust fan is in fluid communication with the internal space. First and second spaced apart rows of product containers are disposed on either side of the exhaust fan to form an airflow aisle with an open end. A cover extends over the airflow aisle and the open end to form an air plenum tunnel. The exhaust fan is activated to lower the air pressure within the tunnel and pull enclosure air through openings in and between the product containers and over and around the food product. The exhaust fan further circulates exhaust air over cooling coils and returns exhaust air to the internal space of the enclosure. | 08-27-2009 |
20110123698 | PROCESS AND APPARATUS FOR PRETREATMENT OF FRESH FOOD PRODUCTS - A method and apparatus for pretreating a fresh food product to relieve the internal (turgor) pressure and adjust the product temperature Invention has an enclosure with an internal space, an air inlet and an air outlet An exhaust fan is in fluid communication with the internal space Rows of product containers are disposed on either side of the exhaust fan to form an airflow aisle with an open end. A cover extends over the airflow aisle and the open end to form an air plenum tunnel. The exhaust fan is activated to lower the air pressure within the tunnel and pull enclosure air through openings in and between the product containers and over and around the food product. The exhaust fan further circulates exhaust air over cooling coils and returns exhaust air to the internal space of the enclosure. An air conditioning mechanism is attached to the enclosure outlet | 05-26-2011 |
Jian Meng, Gastonia, NC US
Patent application number | Description | Published |
---|---|---|
20110027524 | Spliced Fiber Glass Rovings And Methods And Systems For Splicing Fiber Glass Rovings - The invention relates to spliced fiber glass rovings and systems and methods for splicing rovings. In one embodiment, a method for joining fiber glass rovings comprises overlapping a leading end of a first roving with a trailing end of a second roving to create an overlapped region; pneumatically splicing a portion of the overlapped region to form a spliced region; and applying an adhesive to the spliced region. In one embodiment, a spliced fiber glass roving comprises a spliced region comprising a plurality of glass fibers of a leading end of a first roving intertwined with a plurality of glass fibers of a trailing end of a second roving, wherein the spliced region is between about 1 and 20 centimeters long and has a tensile strength between about 50 and 150% of the first roving prior to splicing. | 02-03-2011 |
20120017763 | Filtration Media and Applications Thereof - In some embodiments, the present invention provide filtration media for the treatment of flue gas streams and methods of making and using the same. In one embodiment, a filtration medium comprises a pollutant absorbent layer comprising a plurality of activated carbon fibers, at least one woven fabric, and at least one non-woven fabric, wherein the pollutant absorbent layer is positioned between the at least one woven fabric and the at least one non-woven fabric. | 01-26-2012 |
20120067220 | Filtration Media And Applications Thereof - In some embodiments, the present invention provides filtration media for the treatment of flue gas streams and methods of making and using the same. In one embodiment, a filtration medium comprises a pollutant absorbent layer comprising a plurality of activated carbon fibers, a first woven fabric, and a second woven fabric, wherein the pollutant absorbent layer is positioned between the first woven fabric and the second woven fabric. | 03-22-2012 |
Jianhao Meng, Cos Cob, CT US
Patent application number | Description | Published |
---|---|---|
20110035296 | ENHANCED NETWORK BASED PROMOTIONAL TRACKING SYSTEM - A novel communications network tracks and manages Merchant and Affiliate promotional efforts in a seamless, integrated fashion. Operative characteristics include central control over promotional Java-based presentations or similar to be easily applied across a broad network of connected Affiliate sites. The system accomplishes this, in part, by providing a selective API for use in wrapping the promotional links. In accordance with this protocol, these links may be hosted by the Clearinghouse or Merchant, and sourced from a variety of third-party vendors. | 02-10-2011 |
Jianhao Meng, Riverside, CT US
Patent application number | Description | Published |
---|---|---|
20090030584 | Multi-functional Display for Tachometer - A novel display apparatus and method that enables the operator to shift gears smoothly on motor vehicles is described. The display shows engine revolutions per minute (RPM) at various traveling speeds for any gears all in one dial. The display may also show shifting paths for different driving styles. The static version of the display may be overlaid on top of existing tachometer. The dynamic version of display runs on portable devices with Global Positioning System (GPS) will show optimal RPM and shift indicator continuously. Further, the dynamic display is wireless networked to provide real-time driving instructions. | 01-29-2009 |
Jiayuan Meng, Evanston, IL US
Patent application number | Description | Published |
---|---|---|
20110219221 | Dynamic warp subdivision for integrated branch and memory latency divergence tolerance - Dynamic warp subdivision (DWS), which allows a single warp to occupy more than one slot in the scheduler without requiring extra register file space, is described. Independent scheduling entities also allow divergent branch paths to interleave their execution, and allow threads that hit in the cache or otherwise have divergent memory-access latency to run ahead. The result is improved latency hiding and memory level parallelism (MLP). | 09-08-2011 |
Jiayuan Meng, Charlottesville, VA US
Patent application number | Description | Published |
---|---|---|
20100088492 | SYSTEMS AND METHODS FOR IMPLEMENTING BEST-EFFORT PARALLEL COMPUTING FRAMEWORKS - Implementations of the present principles include Best-effort computing systems and methods. In accordance with various exemplary aspects of the present principles, a application computation requests directed to a processing platform may be intercepted and classified as either guaranteed computations or best-effort computations. Best-effort computations may be dropped to improve processing performance while minimally affecting the end result of application computations. In addition, interdependencies between best-effort computations may be relaxed to improve parallelism and processing speed while maintaining accuracy of computation results. | 04-08-2010 |
Jingjing Meng, Evanston, IL US
Patent application number | Description | Published |
---|---|---|
20090254832 | Method and Apparatus for Collaborative Design of an Avatar or Other Graphical Structure - A method and apparatus for collaborative design of a graphical structure is by users of a network. First, a description of the graphical structure is downloaded from a network server to client devices of the users. User modifications of the graphical structure are then uploaded to the network sever from the client devices. The modifications from multiple users are aggregated to produce an aggregated modification, which is then used to update the graphical structure. A description of the modifications may be a text-based description, in which case it is mapped to a numerical description of the modifications. Alternatively, the descriptions of the modifications may be numerical values. The modifications from a plurality of users (received during a specified time period) may be aggregated by calculating a statistical measure of numerical values corresponding to the modifications. The graphical structure may be an avatar, for example. | 10-08-2009 |
20110239115 | SELECTING AN AVATAR ON A DISPLAY SCREEN OF A MOBILE DEVICE - Disclosed are techniques that allow the user of a mobile device to select an avatar within a virtual world presented on the display screen of the mobile device. In some embodiments, a user manipulates a thumbwheel. As the thumbwheel is turned, the avatars on the display screen are highlighted one after another. The user then presses a thumbwheel button to select a desired avatar. Some embodiments allow the user to select more than one avatar at a time. Several highlighting techniques are available. In some embodiments, the user uses speech commands instead of a thumbwheel to highlight the avatars one by one. Speech input is also used to select one or more avatars. Some devices support a touch-screen interface. Embodiments for these devices allow the user to select an avatar by, for example, drawing an arc enclosing the avatar. | 09-29-2011 |
Jun Meng, Bellevue, WA US
Patent application number | Description | Published |
---|---|---|
20120026896 | METHODS AND APPARATUS FOR POWER CONTROL IN MULTI-CARRIER WIRELESS SYSTEMS - Methods and apparatus disclosed maximize the capacity of serving cells and minimize inter-cell interferences due to power emission from serving cells in a multi-carrier, multi-cell communication system. The control methods and apparatus take into account various factors such as cell configuration, frequency reuse, geometry and path-loss information, transmission priority, subchannel configuration, feedback from other cells, or any combination thereof, and produce signals that control the transmission power levels and the modulation and coding of transmitted signals. | 02-02-2012 |
20140301220 | METHOD AND APPARATUS FOR INTERFERENCE CONTROL IN A MULTI-CELL COMMUNICATION SYSTEM - Methods and apparatus disclosed maximize the capacity of serving cells and minimize inter-cell interferences due to power emission from serving cells in a multi-carrier, multi-cell communication system. The control methods and apparatus take into account various factors such as cell configuration, frequency reuse, geometry and path-loss information, transmission priority, subchannel configuration, feedback from other cells, or any combination thereof, and produce signals that control the transmission power levels and the modulation and coding of transmitted signals. | 10-09-2014 |
Ling-Jian Meng, Champaign, IL US
Patent application number | Description | Published |
---|---|---|
20090140157 | IONIZING RADIATION SENSOR - A system that incorporates teachings of the present disclosure may include, for example, an ionizing radiation sensor having a first scintillator for generating photons from incoming ionizing radiation, an imaging intensifier for amplifying the photons, and an electron-multiplying charge-coupled device (EMCCD) coupled to the imaging intensifier for sensing the amplified photons generated by the imaging intensifier. Additional embodiments are disclosed. | 06-04-2009 |
20110188629 | METHOD AND APPARATUS FOR MEASURING PROPERTIES OF A COMPOUND - A system that incorporates teachings of the present disclosure may include, for example, an apparatus having a collimator having at least one aperture and a fluorescence detector. The collimator can be positioned next to a compound. The compound can emit fluorescence X-rays when impacted by an X-ray beam generated by an X-ray source. The collimator can absorb at least a first portion of the fluorescence X-rays emitted by the compound and release at least a second portion of the fluorescence X-rays at the at least one aperture. The second portion of the fluorescence X-rays released by the at least one aperture have known directional information based on a position of the collimator. The fluorescence detector can detect the second portion of the fluorescence X-rays released by the at least one aperture. A three-dimensional (3-D) rendering of an elemental distribution of the compound can be determined from the fluorescence X-rays detected and the directional information. Additional embodiments are disclosed. | 08-04-2011 |
20130284938 | DETECTOR APPARATUS HAVING A HYBRID PIXEL-WAVEFORM READOUT SYSTEM - A gamma ray detector apparatus comprises a solid state detector that includes a plurality of anode pixels and at least one cathode. The solid state detector is configured for receiving gamma rays during an interaction and inducing a signal in an anode pixel and in a cathode. An anode pixel readout circuit is coupled to the plurality of anode pixels and is configured to read out and process the induced signal in the anode pixel and provide triggering and addressing information. A waveform sampling circuit is coupled to the at least one cathode and configured to read out and process the induced signal in the cathode and determine energy of the interaction, timing of the interaction, and depth of interaction. | 10-31-2013 |
Lingui Meng, Cleveland, OH US
Patent application number | Description | Published |
---|---|---|
20100228011 | BENIGN SOLVENTS FOR FORMING PROTEIN STRUCTURES - A benign solvent for dissolving proteins comprises alcohol, salt and water. The ratio by volume of water to alcohol is between about ninety-nine-to-one and about one-to-ninety-nine. A salt concentration is between near zero moles per liter and the maximum salt concentration soluble in water. The amount of protein by weight as compared to the mixture of water and alcohol is between near zero percent and about 25 percent. A method for forming a protein structure from a benign solvent comprises forming a benign solvent from water, alcohol, and salt; and dissolving a protein in the benign solvent to form a protein solution. The method further comprises extracting the protein from the protein solution; and arranging the protein into a protein structure. | 09-09-2010 |
Ming Meng, Novi, MI US
Patent application number | Description | Published |
---|---|---|
20090018810 | METHOD FOR DETERMINING A SKY VIEW OF AN ANTENNA - A method for determining the amount of open sky view of an antenna in an automotive vehicle. A computer simulation of the vehicle objects that are non-transmissive to electromagnetic radiation is first created while a simulated antenna is also positioned within the computer simulation. Thereafter, a plurality of spheres, each having a different radius, are simulated between a position adjacent the antenna and to a position outside the vehicle. All of the vehicle objects are identified for each sphere and the area saved to memory. Finally, the area of each object is projected onto an outer sphere and these projected areas are then summed. The sky view is then calculated by comparing the amount of the projected area on the outermost sphere and the sky view result is then displayed to the user. | 01-15-2009 |
20130190973 | SYSTEM AND METHOD FOR DETECTING POWER INTEGRATOR MALFUNCTION - A system and a method for diagnosing and isolating a power integrator malfunction are herein provided. The system includes a controller for processing inputs from vehicle electronic control units (ECUs) to actuate semiconductor switching elements to further actuate vehicle electrical systems. The switching elements are in connection with the controller and actuated by a low current signal to actuate a high current circuit to drive an electrical load. Additional semiconductor devices are connected the switching devices for the purpose of monitoring overcurrent, overtemperature, and electromagnetic interference conditions that may affect the switching elements. A communications module is provided to send and receive communications relating to conditions affecting the switching elements over a communications bus. A display connected to the communications bus is operable to display conditions affecting the switching elements. | 07-25-2013 |
Ming Michael Meng, Novi, MI US
Patent application number | Description | Published |
---|---|---|
20120003950 | METHOD AND SYSTEM FOR A RADIO TRANSMISSION EMULATOR - The present invention relates to a method and system for a radio transmission emulator. In one embodiment, the present invention includes a radio transmission emulator system. The radio transmission emulator system includes a radio transmission emulator, an automobile, and/or a radio data analysis unit. The automobile can include a radio receiving unit. The radio transmission emulator generates a field simulation signal which simulates interferences. The field simulation signal is transmitted from the radio transmission emulator to the radio receiving unit. The radio receiving unit generates the radio data based on the field simulation signal. The radio data analysis unit analyzes the radio data to determine whether adjustments should be made to the radio receiving unit. | 01-05-2012 |
20140107982 | DETERMINING THE ELECTROMAGNETIC FIELD IN A COMPUTER AIDED DESIGN ENVIRONMENT - Examples of the invention include methods and apparatus for determining an electromagnetic field, such as a magnetic field, at a selected location within computer-aided design (CAD) data. An example approach may include selecting a location by clicking on, or otherwise selecting the location within a visual representation of the CAD data, selecting one or more electrical components within the CAD data, retrieving electrical current data and distance data for each of the selected electrical components, and determining the electromagnetic field at the selected location using electromagnetic theory. Examples of the invention allow rapid determination of potential electromagnetic noise problems in the CAD design stage, before prototyping and without the complexity of a full 3D electromagnetic simulation. | 04-17-2014 |
Qingjiang Meng, Sugar Land, TX US
Patent application number | Description | Published |
---|---|---|
20110040126 | NOVEL MERCAPTAN-BASED CORROSION INHIBITORS - Corrosion of both ferrous and non-ferrous metals, induced by a variety of corrosive aqueous-based environments, may be inhibited or controlled through use of corrosion inhibiting compositions comprising at least one member of certain formula-specified categories of mercaptan-based compounds. Where the compounds are appropriately selected, and particularly at low inhibitor concentrations, the compositions may inhibit corrosion to a degree that is comparable to or significantly greater than the inhibition provided by an equal amount of certain other corrosion inhibitor compounds. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 02-17-2011 |
Quanxin Meng, Richland, WA US
Patent application number | Description | Published |
---|---|---|
20090007281 | Animal Model for Assessing Copd-Related Diseases - Methods of diagnosis, markers, and screening techniques and animal models for assessing the severity and/or progression or regression of chronic obstructive pulmonary disease (COPD) and COPD-related diseases are disclosed. | 01-01-2009 |
Shicong Meng, Atlanta, GA US
Patent application number | Description | Published |
---|---|---|
20110167421 | Dynamic Scaling of Management Infrastructure in Virtual Environments - Methods, systems, and computer programs for performing management tasks in a virtual infrastructure are presented. The method includes detecting an increase, beyond a predetermined threshold, in the number of tasks waiting to be processed by a first virtual center (VC), which executes as a virtual machine (VM) in the virtual infrastructure. Further, the method includes operations for spawning one or more additional VCs executing as VMs in the virtual infrastructure and for distributing the managed objects handled by the first VC among the additional VCs. The tasks waiting to be processed are reallocated among the first VC and the additional VCs, and the reallocated tasks are then processed by the corresponding VC. | 07-07-2011 |
20140130048 | DYNAMIC SCALING OF MANAGEMENT INFRASTRUCTURE IN VIRTUAL ENVIRONMENTS - Methods, systems, and computer programs for performing management tasks in a virtual infrastructure are presented. The method includes detecting a decrease, below a predetermined threshold, in a number of tasks waiting to be processed by a plurality of virtual centers (VCs) executing as virtual machines (VMs) in a virtual infrastructure, wherein each of the plurality of VCs is a management VM for the managed objects of the virtual infrastructure. The method further includes, based on the detected decrease in the number of tasks waiting to be processed, selecting one or more VCs of the plurality of VCs to be removed, distributing managed objects handled by the selected one or more VCs to one or more non-selected VCs of the plurality of VCs, and removing the selected one or more VCs. | 05-08-2014 |
Shuang Meng, Boise, ID US
Patent application number | Description | Published |
---|---|---|
20080251828 | ENHANCED ATOMIC LAYER DEPOSITION - A method of enhanced atomic layer deposition is described. In an embodiment, the enhancement is the use of plasma. Plasma begins prior to flowing a second precursor into the chamber. The second precursor reacts with a prior precursor to deposit a layer on the substrate. In an embodiment, the layer includes at least one element from each of the first and second precursors. In an embodiment, the layer is TaN. In an embodiment, the precursors are TaF | 10-16-2008 |
20100092891 | PITCH REDUCED PATTERNS RELATIVE TO PHOTOLITHOGRAPHY FEATURES - Differently-sized features of an integrated circuit are formed by etching a substrate using a mask which is formed by combining two separately formed patterns. Pitch multiplication is used to form the relatively small features of the first pattern and conventional photolithography used to form the relatively large features of the second pattern. Pitch multiplication is accomplished by patterning a photoresist and then etching that pattern into an amorphous carbon layer. Sidewall spacers are then formed on the sidewalls of the amorphous carbon. The amorphous carbon is removed, leaving behind the sidewall spacers, which define the first mask pattern. A bottom anti-reflective coating (BARC) is then deposited around the spacers to form a planar surface and a photoresist layer is formed over the BARC. The photoresist is next patterned by conventional photolithography to form the second pattern, which is then is transferred to the BARC. The combined pattern made out by the first pattern and the second pattern is transferred to an underlying amorphous silicon layer and the pattern is subjected to a carbon strip to remove BARC and photoresist material. The combined pattern is then transferred to the silicon oxide layer and then to an amorphous carbon mask layer. The combined mask pattern, having features of difference sizes, is then etched into the underlying substrate through the amorphous carbon hard mask layer. | 04-15-2010 |
20100210111 | PITCH REDUCED PATTERNS RELATIVE TOPHOTOLITHOGRAPHY FEATURES - Differently-sized features of an integrated circuit are formed by etching a substrate using a mask which is formed by combining two separately formed patterns. Pitch multiplication is used to form the relatively small features of the first pattern. Pitch multiplication is accomplished by patterning an amorphous carbon layer. Sidewall spacers are then formed on the amorphous carbon sidewalls which are then removed; the sidewall spacers defining the first mask pattern. A bottom anti-reflective coating (BARC) is then deposited to form a planar surface and a photoresist layer is formed over the BARC. The photoresist is next patterned by conventional photolithography to form the second pattern, which is transferred to the BARC. The combined pattern is transferred to an underlying amorphous silicon layer. The combined pattern is then transferred to the silicon oxide layer and then to an amorphous carbon mask layer. The combined mask pattern, is then etched into the underlying substrate. | 08-19-2010 |
20100213574 | HIGH DIELECTRIC CONSTANT TRANSITION METAL OXIDE MATERIALS - A transition metal oxide dielectric material is doped with a non-metal in order to enhance the electrical properties of the metal oxide. In a preferred embodiment, a transition metal oxide is deposited over a bottom electrode and implanted with a dopant. In a preferred embodiment, the metal oxide is hafnium oxide or zirconium oxide and the dopant is nitrogen. The dopant can convert the crystal structure of the hafnium oxide or zirconium oxide to a tetragonal structure and increase the dielectric constant of the metal oxide. | 08-26-2010 |
20110108929 | ENHANCED ATOMIC LAYER DEPOSITION - Atomic layer deposition is enhanced using plasma. Plasma begins prior to flowing a second precursor into a chamber. The second precursor reacts with a first precursor to deposit a layer on a substrate. The layer may include at least one element from each of the first and second precursors. The layer may be TaN, and the precursors may be TaF | 05-12-2011 |
20110117743 | MULTIPLE DEPOSITION FOR INTEGRATION OF SPACERS IN PITCH MULTIPLICATION PROCESS - Pitch multiplication is performed using a two step process to deposit spacer material on mandrels. The precursors of the first step react minimally with the mandrels, forming a barrier layer against chemical reactions for the deposition process of the second step, which uses precursors more reactive with the mandrels. Where the mandrels are formed of amorphous carbon and the spacer material is silicon oxide, the silicon oxide is first deposited by a plasma enhanced deposition process and then by a thermal chemical vapor deposition process. Oxygen gas and plasma-enhanced tetraethylorthosilicate (TEOS) are used as reactants in the plasma enhanced process, while ozone and TEOS are used as reactants in the thermal chemical vapor deposition process. The oxygen gas is less reactive with the amorphous carbon than ozone, thereby minimizing deformation of the mandrels caused by oxidation of the amorphous carbon. | 05-19-2011 |
20120256309 | Integrated Circuit Having Pitch Reduced Patterns Relative To Photolithography Features - An integrated circuit having differently-sized features wherein the smaller features have a pitch multiplied relationship with the larger features, which are of such size as to be formed by conventional lithography. | 10-11-2012 |
20130140646 | TRANSISTOR WITH REDUCED DEPLETION FIELD WIDTH - Devices such as transistors having an oxide layer that provide a depletion field in a conduction channel. A barrier layer is formed over the oxide layer. A gate electrode is formed over the barrier layer. The barrier layer and gate electrode are configured to reduce the width of the depletion field absent a voltage applied to the gate electrode. | 06-06-2013 |
Tze-Chiang Meng, Lino Lakes, MN US
Patent application number | Description | Published |
---|---|---|
20110021555 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORTER DOSING REGIMENS FOR TREATING ACTINIC KERATOSES - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 01-27-2011 |
20110207766 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 08-25-2011 |
20110257216 | 2 x 2 x 2 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257217 | 3 x 3 x 3 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257218 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257219 | LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORUMLATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110263633 | UP TO SIX WEEKS TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSES WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263634 | LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263635 | METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263636 | 3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263637 | UP TO SIX WEEKS DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110319811 | COMBINATION THERAPY WITH CRYOSURGERY AND LOW DOSAGE STRENGTH IMIQUIMOD TO TREAT ACTINIC KERATOSIS - The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis (“AK”). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion-directed therapy. | 12-29-2011 |
20120289538 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 11-15-2012 |
20120329823 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329824 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329825 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20130190715 | COMBINATION THERAPY WITH LOW DOSAGE STRENGTH IMIQUIMOD AND PHOTODYNAMIC THERAPY TO TREAT ACTINIC KERATOSIS - This disclosure is directed to the use of complementary or combination photodynamic therapy and topical therapy with a lower dosage strength imiquimod formulation for treating actinic keratosis. | 07-25-2013 |
20130210855 | 2 X 2 X 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 08-15-2013 |
Wayne Meng, Fogelsville, PA US
Patent application number | Description | Published |
---|---|---|
20120029376 | Personal Spirometer - A portable hand-held spirometer is disclosed for use in taking respiratory tests and storing and displaying test results. The configuration of the spirometer includes handgrips that are positioned to ensure that the user is properly positioned to provide maximum breathing required for valid test results to be obtained. The spirometer also includes a progressively illuminated indicator that can be viewed by the user during a test to provide an indication in real-time to the user of the expected/desired duration of the exhalation or inhalation test. The indicator is completely illuminated only when the measured accumulated volume of air passing through the spirometer equals a predicted volume determined based on the age, gender, height, weight and ethnicity of the user stored in the spirometer. The structures and arrangement of a turbine assembly and sensors is also disclosed. Further, a method of receiving, storing and displaying information on the spirometer via a color touch screen display is also disclosed. | 02-02-2012 |
20140316296 | Personal Spirometer - A spirometer for correlating test results with other user date to indicate a relationship, said spirometer comprising: (a) a processor; (b) memory operatively connected to said processor and configured with instruction to instruct the processor to perform the following steps: (i) recording spirometer results of a user; (ii) correlating said results with user data, said user data comprising at least one of a medication log, a medical diary, a baseline performance for said user provided by a healthcare provider, or other results from other testing devices; and (iii) indicating a relationship between said results and said user data. | 10-23-2014 |
Wei Meng, Pennington, NJ US
Patent application number | Description | Published |
---|---|---|
20110118211 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure | 05-19-2011 |
20120142636 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure | 06-07-2012 |
20130029939 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R | 01-31-2013 |
20130143843 | ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS - The present invention provides compounds of Formula (I): | 06-06-2013 |
Weihong Meng, Katy, TX US
Patent application number | Description | Published |
---|---|---|
20100006299 | Dual Subsea Production Chokes for HPHT Well Production - Configurations and methods for subsea hydrocarbon production at high pressure wells are contemplated in which production control is achieved by implementing two choke valves in series between the wellhead and the riser The first production choke reduces pressure from well pressure to a reduced pressure, while the second production choke further reduces the pressure from the reduced pressure to riser pressure. The first production choke is preferably coupled to the production tree, and the second production choke is coupled to production tree, a subsea pipeline-end device (e.g., PLET or PLEM), a well jumper, or a flowline jumper. | 01-14-2010 |
Wen Jin Meng, Baton Rouge, LA US
Patent application number | Description | Published |
---|---|---|
20100288479 | Metal-Based Microchannel Heat Exchangers Made by Molding Replication and Assembly - Compression molding of metals is used to make microchannel heat exchangers. Heat transfer can be improved by employing controlled microchannel surface roughness. Flux-free bonding is achieved using a eutectic thin-film intermediate layer. Seals are leak-tight, mechanically strong, and uniform across multiple contact areas. The metal heat exchangers may be mass-produced inexpensively, and are useful for applications including the cooling of computer chips and other high-power electronic devices, air conditioning, refrigeration, condenser plates, radiators, fuel cell heat management, and instant water heating. | 11-18-2010 |
20110174040 | Continuous Microscale Forming of Metal-Based Microchannels and Other Microchannel Devices - A process is disclosed for producing metal-based, high-aspect-ratio microscale structures (HARMs), for example microchannels in a heat exchanger. The preferred manufacturing method operates in a continuous mode, and employs low-temperature rolling of metals. A process is disclosed for bonding metal microchannel sheets or plates to flat metal sheets or plates to form single-, double-, and multiple-layered microchannel structures. The process can operate at much lower temperatures than prior methods of compression microscale molding of metals, at room temperature or even lower. | 07-21-2011 |
Wilson Meng, Sewickley, PA US
Patent application number | Description | Published |
---|---|---|
20120141549 | OLIGONUCLEOTIDES TARGETING ASTHMA INFLAMMATION PROCESSES - The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation. | 06-07-2012 |
Xiang-Jin Meng, Blacksburg, VA US
Patent application number | Description | Published |
---|---|---|
20080226666 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 09-18-2008 |
20100034845 | AVIAN HEPATITIS E VIRUS, VACCINES AND METHODS OF PROTECTING AGAINST AVIAN HEPATITIS-SPLENOMEGALY SYNDROME AND MAMMALIAN HEPATITIS E - The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for propagating, inactivating or attenuating a hepatitis E virus comprising inoculating an embryonated chicken egg with a live, pathogenic hepatitis E virus and recovering the virus or serially passing the pathogenic virus through additional embryonated chicken eggs until the virus is rendered inactivated or attenuated. Further, this invention concerns diagnostic reagents for detecting an avian hepatitis E viral infection or diagnosing hepatitis-splenomegaly syndrome in an avian or mammalian species comprising an antibody raised or produced against the immunogenic compositions and antigens such as ORF2 proteins expressed in a baculovirus vector, | 02-11-2010 |
20100055122 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 03-04-2010 |
20100317054 | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF - The present invention relates to the cloning, identification and characterization of the unique and entire genomic sequences encoding new porcine DC-SIGN and LSECtin proteins, including the novel nucleotide sequences of the full-length cDNA and genes of both pDC-SIGN gene and pLSECtin. Also provided are the nucleic acid molecules encoding newly discovered porcine ICAM-3 isoforms from porcine monocyte-derived dendritic cells and the use thereof. Specifically, the invention is drawn to an isolated nucleic acid molecule comprising a nucleotide sequence encoding one or more of porcine DC-SIGN, porcine ICAM-3, porcine LSECtin, a complement of the nucleotide sequence or a functional, defined portion of the nucleotide sequence or a protein fusion product linked to a protein that may be of porcine or human origin. Methods for isolating and cloning the new porcine genes and for using the new nucleotide sequences in improved methods for propagating viruses, particularly enveloped viruses, are additionally described herein. The invention further includes new transfected cells or cell lines that can stably express the porcine proteins, new antibodies and the like. | 12-16-2010 |
20110027312 | CHIMERIC PORCINE CIRCOVIRUS PCV2Gen-1Rep AND USES THEREOF - The present invention relates to a novel chimeric nucleic acid molecule of porcine circovirus (PCV2Gen-1Rep) that embraces a nucleic acid molecule encoding porcine circovirus type 2 (PCV2) which contains a nucleic acid sequence encoding a Rep protein of porcine circovirus type 1 (PCV1), particularly wherein the nucleic acid sequence encoding the Rep protein of PCV1 GO is an open reading frame (ORF) gene and, more particularly, wherein the ORF Rep gene is ORF1. A highly desirable chimeric nucleic acid molecule is constructed by replacing the ORF1 Rep gene of PCV2 by the ORF1 Rep gene of PCV1. The invention also encompasses the biologically functional plasmid or viral vector containing the unique chimeric nucleic acid molecules, suitable host cells transfected by the plasmid or vector, infectious chimeric porcine circoviruses that are produced by the suitable host cells, the process for the production of an immunogenic polypeptide product making use of the new chimera, viral vaccines that protect a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of protecting a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of preparing the unique chimera of PCV2Gen-1Rep and the like. This invention further includes a new method for improving the replication and titer of PCV2 in a cell culture. | 02-03-2011 |
20110045019 | PORCINE TORQUE TENO VIRUS VACCINES AND DIAGNOSIS - The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies. | 02-24-2011 |
20110280905 | LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE - The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD). | 11-17-2011 |
20130142824 | NOVEL MODIFIED LIVE-ATTENUATED VACCINES (MLV) CREATED BY DNA SHUFFLING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) - The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques. Particularly, the present invention provides infectious chimeric viruses generated by DNA shuffling of the GP5 genes of genetically distinct strains of PRRSV; modified live-attenuated vaccines comprise infectious chimeric viruses containing the shuffled GP5 genes and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins); broadly -protective subunit vaccines comprising PRRSV chimeric shuffled GP5 protein and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins). | 06-06-2013 |
20130149334 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 06-13-2013 |
20130315944 | INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2 - The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of | 11-28-2013 |
20140220067 | LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE - The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD). | 08-07-2014 |
Xiangsheng Meng, Chanhassen, MN US
Patent application number | Description | Published |
---|---|---|
20090048459 | METHOD OF MAKING HYDROGENATED METATHESIS PRODUCTS - Disclosed is a method of making hydrogenated metathesis products comprising the steps of: (a) providing a metathesis composition; (b) providing a metathesis catalyst comprising a transition metal; (c) metathesizing at least a portion of the metathesis composition in the presence of the metathesis catalyst to form a first composition comprising one or more metathesis products and a transition metal; (d) hydrogenating at least a portion of the first composition in the presence of a hydrogenation catalyst to form a second composition comprising one or more hydrogenated metathesis products, transition metal, and hydrogenation catalyst; and (e) removing at least a portion of the hydrogenation catalyst from the second composition, wherein the removal of the hydrogenation catalyst removes at least a portion of the transition metal of the metathesis catalyst from the second composition. | 02-19-2009 |
20090298144 | METHODS OF MANUFACTURING DERIVATIVES OF BETA-HYDROXYCARBOXYLIC ACIDS - Preparation of derivatives of β-hydroxycarboxylic acid, including β-hydroxycarboxylic acid esters, α,β-unsaturated carboxylic acid, esters of α,β-unsaturated carboxylic acid, and alkoxy derivatives. | 12-03-2009 |
20130150616 | METHODS OF MANUFACTURING DERIVATIVES OF BETA-HYDROXYCARBOXYLIC ACIDS - Preparation of derivatives of β-hydroxycarboxylic acid, including β-hydroxycarboxylic acid esters, α,β-unsaturated carboxylic acid, esters of α,β-unsaturated carboxylic acid, and alkoxy derivatives. | 06-13-2013 |
Xiangsheng S. Meng, Chanhassen, MN US
Patent application number | Description | Published |
---|---|---|
20090110624 | Processes for Producing Phosphates - There are disclosed methods for producing ammonium, sodium, and/or potassium phosphates that involve reacting phosphate rock with ammonium, sodium and/or potassium hydrogen sulfate. | 04-30-2009 |
20100099910 | CARBOXYLIC ACIDS PREPARED USING A SALT-SPLITTING PROCESS - Processes for preparing carboxylic acids in which a single phase mixture including an ammonium salt of a carboxylic acid is heated in the presence of a non-aqueous solvent to split the salt and form the acid. The acid may be dehydrated to form unsaturated counterparts. | 04-22-2010 |
Xiangwen Meng, Skokie, IL US
Patent application number | Description | Published |
---|---|---|
20110287965 | METHODS AND COMPOSITIONS TO DETECT CLOSTRIDIUM DIFFICILE - Methods for detecting strains of | 11-24-2011 |
Xiangying Meng, Frisco, TX US
Patent application number | Description | Published |
---|---|---|
20110080360 | UNIVERSAL TOUCH INPUT DRIVER - A universal touch input driver includes a device driver interface through which touch data is obtained from a device driver. Also included is a computation module that processes the touch data and converts it into a standardized format. Also included is an application interface through which the standardized touch data is transferred to a touch input application. | 04-07-2011 |
Xianjun Meng, Hockessin, DE US
Patent application number | Description | Published |
---|---|---|
20090087670 | FLUOROALKYL PHOSPHATE COMPOSITIONS - A composition comprising a compound of formula (I) or (II): | 04-02-2009 |
20100129668 | POLYFLUOROETHER-BASED PHOSPHATES - A composition comprising one or more compounds of formula (I) or (II): | 05-27-2010 |
20110200815 | FLUOROALKYL PHOSPHATE COMPOSITIONS - A composition comprising a compound of formula (I) or (II): | 08-18-2011 |
20110293943 | FLUOROPOLYMER ADDITIVE FOR COATINGS - This invention relates to a composition comprising a solvent-based fluoropolymer and its use as a coating additive, and a coating composition comprising the fluoropolymer. The coating composition comprising the solvent-based fluoropolymer provides desirable properties including uniform spreading, and cleanability and increased contact angle to a coated substrate. There is further provided a method of treating a substrate using the coating composition. | 12-01-2011 |
20110293949 | SOLVENT-BASED FLUOROPOLYMER ADDITIVES AND THEIR USE IN COATING COMPOSITIONS - This invention relates to a composition comprising a solvent-based fluoropolymer and its use as a coating additive, and a coating composition comprising the fluoropolymer. The coating composition comprising the solvent-based fluoropolymer provides desirable properties including uniform spreading, and cleanability and increased contact angle to a coated substrate. There is further provided a method of treating a substrate using the coating composition. | 12-01-2011 |
20130112908 | FLUOROPHOSPHATE SURFACTANTS - This invention is directed to a composition capable of imparting surface effects to a liquid by contacting the liquid with a partially fluorinated phosphate with an ammonium cation (NH | 05-09-2013 |
20130210976 | FLUORINATED PHOSPHATES AS SURFACE ACTIVE AGENTS - An improved method for lowering the surface tension of coating compositions wherein a surfactant is contacted with the coating composition, wherein the improvement comprises contacting said coating composition with a surfactant having mono-substituted fluorophosphates present at greater than or equal to 50 mol % than bis-substituted phosphates and substrates treated with the coating composition. | 08-15-2013 |
Xiansheng Meng, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20110215045 | HIGH FIDELITY THROUGH HOLE FILM, AND ASSOCIATED METHOD - A membrane is provided, comprising a first membrane layer having a first side and a second side. The first membrane layer defines a plurality of holes extending along a first axis between the first side and the second side. Each hole is defined by the first membrane layer as a complex three-dimensional shape, and each hole has a diameter of less than about 10 micrometers. The membrane is fabricated by dispersing a liquid polymeric material onto a patterned master template, hardening the polymeric material, and removing it from the master template. The membrane includes through holes which correspond to the structures of the patterned master template in size, cross-sectional and three dimensional shape, orientation, and the like. | 09-08-2011 |
20120206805 | NANOWIRE GRID POLARIZERS AND METHODS FOR FABRICATING THE SAME - A polarizer including a substrate sheet configured with grid elements on at least a first surface, wherein the grid elements have a height to width aspect ratio of at least 1.5:1, and metal coupled with the grid elements, wherein the metal comprises a height to width aspect ratio greater than the aspect ratio of the grid elements of the substrate. | 08-16-2012 |
Xiao-Li Meng, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20100092082 | FRAMEWORK FOR WAVELET-BASED ANALYSIS AND PROCESSING OF COLOR FILTER ARRAY IMAGES WITH APPLICATIONS TO DENOISING AND DEMOSAICING - One aspect of the present invention relates to a new approach to the demosaicing of spatially sampled image data observed through a color filter array. In one embodiment properties of Smith-Barnwell filterbanks may be employed to exploit the correlation of color components in order to reconstruct a sub-sampled image. In other embodiments, the approach is amenable to wavelet-domain denoising prior to demosaicing. One aspect of the present invention relates to a framework for applying existing image denoising algorithms to color filter array data. In addition to yielding new algorithms for denoising and demosaicing, in some embodiments, this framework enables the application of other wavelet-based denoising algorithms directly to the CFA image data. Demosaicing and denoising according to some embodiments of the present invention may perform on a par with the state of the art for far lower computational cost, and provide a versatile, effective, and low-complexity solution to the problem of interpolating color filter array data observed in noise. According to one aspect, a method for processing an image is provided. In one embodiment, image data captured though a color filter array is trans-formed into a series of filterbank subband coefficients, by estimating the filterbank transform for a complete image (which estimation can be shown to be accurate in some embodiments) computation complexity associated with regenerating the complete image can be reduced. In another embodiment, denoising of the CFA image data can occur prior to demosaicing, alternatively denoising can occur in conjunction with demosaicing, or in another alternative, after demosaicing. | 04-15-2010 |
Xiaolong Meng, Wichita, KS US
Patent application number | Description | Published |
---|---|---|
20090053182 | ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME - The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium. | 02-26-2009 |
Xiaoqiao Meng, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20090112780 | DISCOVERING OPTIMAL SYSTEM CONFIGURATIONS USING DECENTRALIZED PROBABILITY BASED ACTIVE SAMPLING - A system and method for optimizing system performance includes applying sampling based optimization to identify optimal configurations of a computing system by selecting a number of configuration samples and evaluating system performance based on the samples. Based on feedback of evaluated samples, a location of an optimal configuration is inferred. Additional samples are generated towards the location of the inferred optimal configuration to further optimize a system configuration. | 04-30-2009 |
20090132865 | Systems and Methods for Automatic Profiling of Network Event Sequences - Systems and methods are disclosed that profile event sequences by creating a mixture model from the event sequences; estimating parameters for the mixture model; and applying the mixture model to profile the event sequences. | 05-21-2009 |
Xingli Meng, Plano, TX US
Patent application number | Description | Published |
---|---|---|
20110217288 | Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease - Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients. | 09-08-2011 |
Xun Meng, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20090023157 | Proteome epitope tags and methods of use thereof in protein modification analysis - Disclosed are methods for reliably detecting the presence of proteins, especially proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided. | 01-22-2009 |
20100184613 | Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis - Disclosed are methods for reliably detecting the presence of proteins, including proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a protein or a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided. | 07-22-2010 |
Yi Meng, Redmond, WA US
Patent application number | Description | Published |
---|---|---|
20100299492 | DISK DRIVE CONDITION REPORTING AND ERROR CORRECTION - A system that facilitates maintaining hard disk drive performance comprises a memory component that includes extensions to at least one protocol associated with a hard disk drive, the extensions enable communications to occur in real-time between an operating system and the hard disk drive. An interface component utilizes the extensions to receive a notification from the hard disk drive and relay the notification to the operating system, the notification relates to an operating parameter of the hard disk drive. | 11-25-2010 |
Yi Meng, Bellevue, WA US
Patent application number | Description | Published |
---|---|---|
20110214017 | FAILED PROCESS REPORTING - An application programming interface (API) that leverages operating system instrumentation to provide a chain of threads and processes may alleviate some debugging complications. Specifically, the chain may start with the first thread in the process that experienced the original failure and end with the last thread upon which the first thread directly or indirectly depends. The API may aid debugging efforts by classifying all threads related or dependent upon an original failed thread into specific categories of failures, requesting further information from the originating OS concerning specific failed threads, and using that information to debug the failed application or process more thoroughly. | 09-01-2011 |
Yufei Meng, Washington, DC US
Patent application number | Description | Published |
---|---|---|
20090110626 | Low Pressure Method of Annealing Diamonds - The present invention relates to method of improving the optical properties of diamond at low pressures and more specifically to a method of producing a CVD diamond of a desired optical quality which includes growing CVD diamond and raising the temperature of the CVD diamond from about 1400° C. to about 2200° C. at a pressure of from about 1 to about 760 torr outside the diamond stability field in a reducing atmosphere for a time period of from about 5 seconds to about 3 hours. | 04-30-2009 |
20100126406 | Production of Single Crystal CVD Diamond at Rapid Growth Rate - In a method of producing diamonds by microwave plasma-assisted chemical vapor deposition which comprises providing a substrate and establishing a microwave plasma ball in an atmosphere comprising hydrogen, a carbon source and oxygen at a pressure and temperature sufficient to cause the deposition of diamond on said substrate, the improvement wherein the diamond is deposited under a pressure greater than 400 torr at a growth rate of at least 200 μm/hr. from an atmosphere which is either essentially free of nitrogen or includes a small amount of nitrogen. | 05-27-2010 |
Yu-Fei Meng, Washington, DC US
Patent application number | Description | Published |
---|---|---|
20100104494 | Enhanced Optical Properties of Chemical Vapor Deposited Single Crystal Diamond by Low-Pressure/High-Temperature Annealing - The method of improving the optical properties of single crystal CVD diamond which comprises annealing the crystals at a temperature of up to 2200° C. and a pressure below 300 torr. | 04-29-2010 |
20110280790 | Production of Large, High Purity Single Crystal CVD Diamond - The invention relates to single crystal diamond with optical quality and methods of making the same. The diamond possesses an intensity ratio of the second-order. Raman peak to the fluorescence background of around 5 or greater. | 11-17-2011 |
Yunjing Meng, Toledo, OH US
Patent application number | Description | Published |
---|---|---|
20110236295 | Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof - Polymeric ionic liquids, methods of making and methods of using the same are disclosed. | 09-29-2011 |
Zhaobo Meng, Katy, TX US
Patent application number | Description | Published |
---|---|---|
20110131020 | DIP GUIDED FULL WAVEFORM INVERSION - A method of determining seismic data velocity models comprising dip-guided full waveform inversion that obtains a better velocity model with less computational requirements. DG-FWI quickly converges to provide a better image, obtains better amplitudes, and relies less on lower frequencies. Improved image quality allows detailed seismic analyses, accurate identification of lithological features, and imaging near artifacts and other anomalies. | 06-02-2011 |
Zhaoxing Meng, Middletown, CT US
Patent application number | Description | Published |
---|---|---|
20100240708 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives - Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a γ-secretase enzyme; or (ii) the production of β-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: | 09-23-2010 |
20130245042 | Positive Allosteric Modulators of MGLUR2 - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. | 09-19-2013 |
Zhaoyang Meng, Lansdale, PA US
Patent application number | Description | Published |
---|---|---|
20120114739 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds. | 05-10-2012 |
20120178744 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS - The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R | 07-12-2012 |
20120322791 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS - The present invention provides Pyrazolopyrimidine Compounds of Formula (I): | 12-20-2012 |
20130150353 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin - This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders. | 06-13-2013 |
20130281474 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN - This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders. | 10-24-2013 |
20140171456 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS - The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds. | 06-19-2014 |
20140309227 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE - The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, R | 10-16-2014 |
Zhuo Meng, Broadview Heights, OH US
Patent application number | Description | Published |
---|---|---|
20090055411 | SYSTEM AND METHOD FOR PRECISELY HANDLING DURATION VALUES - A system and method for handling duration values includes associating a duration value with a start datetime to allow precise duration handling. Thus, a uniform time line approach may be used to handle duration arithmetic, comparisons, or other computations for duration values. For example, the uniform time line approach may characterize a duration value as a difference between two endpoints of a timeline segment having a length equal to the duration value. As a result, duration operations can be carried out with precision and accuracy using simple calendar calculations. | 02-26-2009 |
20090292663 | FUZZY RULE HANDLING - A method to add expression level fuzzy rule processing capability to existing crisp rule engine without requiring extensive modifications to such rule engine. A system and computer implemented method receive a data set at a crisp rule engine. If the data set involves a fuzzy rule, a callback to a fuzzy rule broker is done. The fuzzy rule broker selects one of multiple tailored processing modules for processing the fuzzy rule. The result of processing the fuzzy rule may be converted to a crisp result and returned to the crisp rule engine. | 11-26-2009 |